Nonetheless, this trend was also reported in different studies (7, 10, 14), where both B- and T- cell responses were measured and it was shown that there is a marked immunological impairment in MS individuals treated with fingolimod compared to those treated with natalizumab (7) or IFNβ (10), leading to the limited anti-S antibody production and T-cell activation. This evidence concerns the gene IFNB1 and myeloid sarcoma.